M&A
confidence high
sentiment positive
materiality 0.80
Tarsus closes $270M cash + stock buy of Alkeus; adds Stargardt drug ALK-001
Tarsus Pharmaceuticals, Inc.
- Up-front consideration: $270M cash plus 2,908,692 Tarsus shares to Alkeus equityholders.
- Milestones up to $350M: $250M on US regulatory approval, $100M on first US sale; plus low-to-mid single-digit revenue share.
- Adds ALK-001, Phase 3 oral for Stargardt disease, with FDA Breakthrough, Orphan, Fast Track, Rare Pediatric designations.
- NORTHSTAR Phase 3 trial ongoing; topline data expected 2029.
- Acquisition closed Sept 4, 2026; Alkeus becomes wholly-owned subsidiary.
Featured in Daily 8-K Digest
Selected #5 for 2026-09-10.
Read digest